Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03055299
Other study ID # PRO15070086
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 20, 2017
Est. completion date April 30, 2018

Study information

Verified date July 2018
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the COMprehensive EXercise (COMEX) pilot study is to test feasibility, tolerability and adherence of this novel video-based intra-dialytic chair exercise program for hemodialysis patients over 3 months.


Description:

The investigators incorporated patient-provider preferences of the key stakeholders, and used a multi-disciplinary team with experts in physical therapy, psychology and nephrology to develop a comprehensive exercise program for HD patients. Aim of this pilot study is to assess the feasibility, tolerability and adherence to COMEX over 3 months and inform design of future randomized controlled trial. A secondary goal is to explore molecular mechanisms in muscle and blood of exercise adaptation in HD patients


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date April 30, 2018
Est. primary completion date March 10, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

For patients:

- Age =18 years to 85 years

- Undergoing maintenance hemodialysis for >3 months at one of the participating dialysis sites

- Patients must be willing and able to sign the consent form.

For providers:

- Eligible if they are a registered nurse, dialysis technician, dialysis social worker, dietitian, dialysis unit administrator or nephrologist involved in providing care for one of the patient participants in the study

Exclusion Criteria:

For all patients:

- Uncontrolled BP (>180/100 mm Hg)

- Inadequately dialyzed (Kt/V<1.2)

- History of Intradialytic hypotension (SBP<90mm Hg) or hypertension (SBP>180mmHg) during/post dialysis within last 1 month

- Contraindication to exercise eg unstable angina, uncompensated congestive heart failure

- Refractory/untreated psychiatric disorders

- History of poor adherence to HD treatment.

- Scheduled for living donor kidney transplant, intention to change to peritoneal dialysis, home HD, or plans to relocate to another center within the next 6 months.

- Currently in acute or chronic care hospital

- Life expectancy < 6 months or intention to withdraw dialysis therapy within 6 months.

- Current pregnancy, or actively planning to become pregnant in the next 6 months

- Currently a prisoner

- Current use of investigational drugs or participation in another non-observational clinical trial that contradicts or interferes with the therapies or measured outcomes in this trial

- Unable or unwilling to follow the study protocol for any reason (including mental incompetence)

- Unable or unwilling to provide informed consent or sign IRB-approved consent form

- Has a tunneled dialysis catheter

- If diabetic, blood sugar control is not stable

For patients undergoing biopsy and blood draw:

- Allergy to lidocaine

- Anemia, <10.0 Hgb

- Chronic use of oral corticosteroids or other medication that affect muscle function

- Any bleeding disorder that would contraindicate biopsy or blood draw such as a history of clinically significant bleeding diathesis (e.g. hemophilia A or B, Von Willebrand's Disease or congenital Factor VII deficiency)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
COMEX intervention
Comprehensive Exercise

Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rate Feasibility will be estimated by calculating the % of eligible participants who consent to participate in the study. 3 months
Primary Number of participants with exercise-related adverse events Tolerability will be measured by assessing exercise related side effects - this will be done by weekly patient interviews and review of medical records 3 months
Primary Adherence rate Adherence will be calculated as % of participants who complete the 3 month COMEX intervention. Also, adherence to exercise will be calculated as % of exercise sessions completed 3 months
Secondary Fatigue Self reported fatigue using Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Fatigue questionnaire will be measured at baseline and at 3 months 3 months
Secondary Sleep Self reported sleep using Pittsburgh Sleep Quality Index (PSQI) questionnaire will be measured at baseline and at 3 months 3 months
Secondary Depression Self reported depression using Beck's Depression Inventory -II questionnaire will be measured at baseline and at 3 months 3 months
Secondary Global health Self reported HRQOL using NIH Patient Reported Outcomes Measurement Information System (PROMIS) Adult Global Health questionnaire will be measured at baseline and at 3 months 3 months
Secondary Health related quality of life Self reported HRQOL using Short-Form 36 questionnaire will be measured at baseline and at 3 months 3 months
Secondary Sleep/Wake Behavior by Actigraphy Objective sleep and activity will be measured using actigraphy 3 months
Secondary Physical functioning Will be measured by Short Physical Performance battery at baseline and 3 months 3 months
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Completed NCT03456648 - Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study Phase 2
Completed NCT01252771 - Phosphate Kinetic Modeling 2 Phase 4
Completed NCT00966615 - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00294502 - Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia Phase 4
Completed NCT05011136 - Physician Reimbursement Home Patients
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Completed NCT02278562 - Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 Phase 2
Completed NCT01424787 - Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering) N/A
Terminated NCT00580762 - Bariatric Surgery for ESRD Patients vs Control N/A
Recruiting NCT05339139 - SAfety of Regional Citrate Anticoagulation (SARCA Study) Phase 3
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Recruiting NCT05309785 - Safety and Efficacy of Canagliflozin in Advanced CKD Phase 4
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Not yet recruiting NCT02596386 - Examination of Potassium Levels in Saliva in ESRD Patients N/A
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Active, not recruiting NCT02270515 - Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease N/A
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A